2-methylpentane has been researched along with Cardiovascular Stroke in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bannasch, H; Braig, D; Eisenhardt, SU; Goerendt, K; Habersberger, J; Kolodgie, F; Maurer, V; Peter, K; Scheichl, A; Schmidt, Y; Stark, GB; Thiele, JR; Virmani, R; von Dobschütz, E; Woollard, KJ | 1 |
| Aquilina, JA; Bellotti, V; Cobb, AJ; Gallimore, JR; Gray, GA; Hawkins, PN; Hirschfield, GM; Jenvey, MC; Kahan, MC; Kolstoe, SE; Ley, SV; Myers, RM; Pepys, MB; Polara, A; Robinson, CV; Sabin, CA; Sharif, I; Smith, MD; Tennent, GA; Thompson, D; Wood, SP | 1 |
| Jialal, I; Kitsis, RN | 1 |
3 other study(ies) available for 2-methylpentane and Cardiovascular Stroke
| Article | Year |
|---|---|
Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy.
Topics: Animals; Anti-Inflammatory Agents; Biopolymers; C-Reactive Protein; Carrier Proteins; Cell Adhesion; Cell Membrane; Chemotaxis, Leukocyte; Complement Activation; Endothelial Cells; Hexanes; Humans; Inflammation; Leukocyte Rolling; Lipopolysaccharides; Lysophosphatidylcholines; Male; Membrane Lipids; Muscle, Skeletal; Myocardial Infarction; Myositis; Phospholipase A2 Inhibitors; Phospholipases A2; Phosphorylcholine; Protein Structure, Quaternary; Random Allocation; Rats; Rats, Wistar; Receptors, IgG; Reperfusion Injury | 2014 |
Targeting C-reactive protein for the treatment of cardiovascular disease.
Topics: Animals; C-Reactive Protein; Cardiovascular Diseases; Complement System Proteins; Drug Design; Hexanes; Humans; Male; Models, Molecular; Molecular Conformation; Myocardial Infarction; Phosphorylcholine; Rats; Rats, Wistar | 2006 |
Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein.
Topics: Animals; C-Reactive Protein; Complement Activation; Hexanes; Humans; Myocardial Infarction; Myocardium; Phosphorylcholine; Rats | 2006 |